Entrada Therapeutics insider files Form 144 to offload 0.05% stake

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) – Form 144 filing

An affiliate has filed a Form 144 to sell up to 19,265 common shares through TD Securities (USA) LLC on or after 27 June 2025. The proposed transaction carries an aggregate market value of $133,121.15. The shares were originally acquired on 28 September 2017 via a cash venture investment. With 37,953,417 shares outstanding, the maximum sale equals roughly 0.05 % of the issuer’s float, indicating minimal dilution or price pressure.

No other sales have been reported in the past three months, and the filer states they possess no undisclosed material adverse information. Form 144 is a notice only; it does not obligate the seller to complete the trade and provides no operating or earnings data. Given the small size of the stake, the market impact is expected to be immaterial, though investors often interpret insider intentions to sell as a mildly negative sentiment indicator.

Positive

• None.

Negative

• Insider intent to sell: Filing signals a shareholder’s plan to dispose of shares, which some investors perceive as a bearish sentiment indicator.

Insights

Securities Analyst

TL;DR: Small insider Form 144 sale (0.05% float); signal is marginal, financial impact negligible.

The filing discloses a potential sale of 19,265 TRDA shares worth about $133k—only 0.05 % of outstanding stock. Such notice is routine compliance for affiliates under Rule 144 and carries no forward-looking financial data. Because the stake is tiny relative to the float and no concurrent sales were reported, liquidity or price pressure should be minimal. Nevertheless, any insider-initiated disposal can be viewed as a slight negative sentiment cue. Overall, I classify the update as neutral for valuation purposes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD Securities (USA) LLC 1 Vanderbilt Ave New York NY 10017	19265	133121.15	37953417	06/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/28/2017	Venture Investment	Entrada Therapeutics, Inc.			19265	09/28/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many TRDA shares are being proposed for sale?

The Form 144 covers up to 19,265 common shares.

What is the aggregate market value of the proposed TRDA share sale?

The filing lists an approximate value of $133,121.15.

When is the planned sale date for the TRDA shares?

The filer indicates an approximate sale date of 27 June 2025.

What percentage of Entrada Therapeutics’ outstanding shares does this sale represent?

It represents roughly 0.05 % of the 37,953,417 shares outstanding.

On which exchange will the TRDA shares be sold?

The securities are slated for sale on the NASDAQ.